Yucai Wang, Melissa C. Larson, Steven R. Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar, Ashlee Joseph, Taylor Brooks, Brian T. Hill, David A. Bond, Kami J. Maddocks, Imran Nizamuddin, Brad S. Kahl, Alexey V. Danilov, Christine Argao, Jia Ruan, Christine E. Ryan, Reid W. Merryman, Natalie S. Grover, Nazneen B. Khan, Evguenia Ouchveridze, Aung M. Tun, Sabarish Ayyappan, Eric Mou, Georgios Pongas, Izidore S. Lossos, Zoey I. Harris, Javier Muñoz, Philip Young, Craig A. Portell, Firas Baidoun, Muhamad Alhaj Moustafa, Patrick M. Reagan, Lauren Banaszak, Priyanka A. Pophali, Arash Velayati, Irl Brian Greenwell, Drew G. Gerber, Preetesh Jain, Michael Wang, Mayur Narkhede, Amitkumar Mehta, Anthony Stack, Marcus Messmer, Rahul S. Bhansali, Stefan K. Barta, Tamara K. Moyo, Nilanjan Ghosh, Manali Kamdar, Jacob Anna, Alexander Stanisic, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin
ABSTRACT: The benefit of rituximab maintenance after first-line (1L) bendamustine-rituximab (BR) in patients with mantle cell lymphoma (MCL) remains uncertain, with inconsistent results from the phase 2 MAINTAIN trial and several retrospective studies. We conducted a large retrospective study at 27 US and Canadian academic centers to examine the benefit of rituximab maintenance after BR. A total of 911 patients received 1L BR between 2010 and 2020, and 703 had an objective response and no evidence of disease progression at the 3-month post-BR landmark. Among those, 394 (56%) received rituximab maintenance and 309 (44%) did not, with largely similar baseline patient and disease characteristics. In the landmark analysis, rituximab maintenance was associated with improved event-free survival (EFS; median, 49.9 vs 29.7 months; P< .001) as well as overall survival (OS; median, 109.5 vs 74.2 months; P< .001). The EFS and OS benefits were observed across most of the subgroups. EFS and OS differences were statistically significant in those who achieved a complete response to 1L BR (n = 590; median EFS, 62.7 vs 31.1 months [P< .001]; median OS, 136.1 vs 75.3 months [P< .001]), but the analysis among those who achieved a partial response to 1L BR was limited by the small sample size. These results provide additional evidence for the survival benefit of rituximab maintenance after BR in MCL and support its use in clinical trial design and routine practice.